MedWatch

Novo Seeds invests in Dutch biotech firm with NASH focus again

For the third time, Novo Holding's venture arm Novo Seeds has invested in biotech company Northsea Therapeutics. This will allow the latter to start a phase III study of a candidate within NASH and continue phase I and II studies of other candidates.

Søren Møller, Leading Partner at Novo Seeds | Photo: Novo Holdings / PR

Novo Seeds, the department of Novo Holdings which works with early investments, has expressed confidence in Northsea Therapeutics by investing in it for the third time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs